KLK3 and prostate carcinoma: Many investigations have used TAA mRNA complex DCs to trigger an antitumor response.20,40,44 In one study, DCs were implemented to prostate cancer patients after being transfected with prostate-specific antigen (PSA) TAA, and PSA-specific T cell response was induced in six of seven patients.